The expression levels of JunB, JunD and p-c-Jun are positively correlated with tumor cell proliferation in diffuse large B-cell lymphomas

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019–5032.
   PubMed Web of Science ®Google Scholar
• Nogai H, Dörken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1803–1811.
   PubMed Web of Science ®Google Scholar
• Barton S, Hawkes EA, Wotherspoon A, et al. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? Oncologist 2012;17:1562–1573.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Kwong YL, Younes A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol 2014;93:1263–1277.
   PubMed Web of Science ®Google Scholar
• Said JW. AggressiveB-cell lymphomas: how many categories do we need? Mod Pathol 2013;26(Suppl. 1):S42–56.
   PubMedGoogle Scholar
• Martelli M, Ferreri AJ, Agostinelli C, et al. Diffuselarge B-celllymphoma. Crit Rev Oncol Hematol 2013;87:146–171.
   PubMed Web of Science ®Google Scholar
• Monti S, Chapuy B, Takeyama K, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuselarge B cell lymphoma. Cancer Cell 2012;22:359–372.
   PubMed Web of Science ®Google Scholar
• Lim KH, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev 2012;246:359–378.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn, Lyon, France: International Agency for Research on Cancer (IARC) Press; 2008.
   Google Scholar
• Meixner A, Karreth F, Kenner L, et al. JunD regulates lymphocyte proliferation and T helper cell cytokine expression. EMBO J 2004;23:1325–1335.
   PubMed Web of Science ®Google Scholar
• Piechaczyk M, Farràs R. Regulation and function of JunB in cell proliferation. Biochem Soc Trans 2008;36:864–867.
   PubMed Web of Science ®Google Scholar
• Shaulian, E. AP-1: the Jun proteins: oncogenes or tumor suppressors in disguise? Cell. Signal 2010;22:894–899.
   PubMed Web of Science ®Google Scholar
• Shaulian, E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390–2400.
   PubMed Web of Science ®Google Scholar
• Hernandez JM, Floyd DH, Weilbaecher KN, et al. Multiple facets of JunD gene expression are atypical among AP-1 family members. Oncogene 2008;27:4757–4567.
   PubMed Web of Science ®Google Scholar
• Arguni E, Arima M, Tsuruoka N, et al. JunD/AP-1 and STAT3 are the major enhancer molecules for high Bcl6 expression in germinal center B cells. Int Immunol 2006;18:1079–1089.
   PubMed Web of Science ®Google Scholar
• Ci W, Polo JM, Cerchietti L, et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 2009;113:5536–5548.
   PubMed Web of Science ®Google Scholar
• Blonska M, Zhu Y, Chuang HH, et al. Jun-regulated genes promote interaction of diffuselarge B-cell lymphoma with the micro- environment. Blood 2014;125:981–991. pii: blood–2014–04–568188.
   PubMed Web of Science ®Google Scholar
• Trøen G, Nygaard V, Jenssen TK, et al. Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma. J Mol Diagn 2004;6:297–307.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Higuchi T, Oiso N, et al. Expression and function of FRA2/JUND in cutaneous T-cell lymphomas. Anticancer Res 2012;32:1367–1373.
   PubMed Web of Science ®Google Scholar
• Mao X, Orchard G, Lillington DM, et al. BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dermatol 2004;151:546–556.
   PubMed Web of Science ®Google Scholar
• Mao X, Orchard G. Abnormal AP-1 protein expression in primary cutaneous B-cell lymphomas. Br J Dermatol 2008;159:145–151.
   PubMed Web of Science ®Google Scholar
• Mao X, Orchard G, Mitchell TJ, et al. A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. J Cutan Pathol 2008;35:899–910.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Ouyang J, Juszczynski P, et al. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res 2008;14:3338–3344.
   PubMed Web of Science ®Google Scholar
• Szremska AP, Kenner L, Weisz E. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood 2003;102:4159–4165.
   PubMed Web of Science ®Google Scholar
• Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002;21: 4104–4113.
   PubMed Web of Science ®Google Scholar
• Rassidakis GZ, Thomaides A, Atwell C, et al. JunB expression is a common feature of CD30 + lymphomas and lymphomatoid papulosis. Mod Pathol 2005;18:1365–1370.
   PubMed Web of Science ®Google Scholar
• Drakos E, Leventaki V, Schlette EJ, et al. C-Jun expression and activation are restricted to CD30 + lymphoproliferative disorders. Am J Surg Pathol 2007;31:447–453.
   PubMed Web of Science ®Google Scholar
• Mao X, Orchard G, Lillington DM, et al. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 2003;101:1513–1519.
   PubMed Web of Science ®Google Scholar
• Mao X, Orchard G, Russell-Jones R, et al. Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas. Br J Dermatol 2007;157:914–921.
   PubMed Web of Science ®Google Scholar
• Leventaki V, Drakos E, Karanikou M, et al. c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma. Hum Pathol 2014;45:565–572.
   PubMed Web of Science ®Google Scholar
• Leventaki V, Drakos E, Medeiros LJ, et al. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. Blood 2007;110: 1621–1630.
   PubMed Web of Science ®Google Scholar
• Hsu FY, Johnston PB, Burke KA, et al. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin anaplastic lymphoma kinase mediated JunB level in a cell type-specific manner. Cancer Res 2006;66:9002–9008.
   PubMed Web of Science ®Google Scholar
• Staber PB, Vesely P, Haq N, et al. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 2007;110:3374–3383.
   PubMed Web of Science ®Google Scholar
• Atsaves V, Lekakis L, Drakos E, et al. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma. Br J Haematol 2014;167:514–523.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Ogawa Y, Ito K, et al. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed–Sternberg cells. Am J Pathol 2003;163:633–641.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Sasaki M, Itoh K, et al. JunB induced by constitutive CD30 extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin lymphoma. Cancer Res 2005;65:7628–7634.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Itoh K, Togano T, et al. Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Am J Pathol 2012;180:831–838.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Ogawa Y, Itoh K, et al. Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma. Lab Invest 2008;88:48–57.
   PubMed Web of Science ®Google Scholar
• Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs)-a family of adapter proteins that regulates life and death. Genes Dev 1998;12:2821–2830.
   PubMed Web of Science ®Google Scholar
• Bai M, Vlachonikolis J, Agnantis NJ, et al. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol 2001;14:1105–1113.
   PubMed Web of Science ®Google Scholar
• Bai M, Tsanou E, Agnantis NJ, et al. Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferative activity and apoptosis status in diffuse large B-cell lymphomas. Histol Histopathol 2003:18;449–457.
   PubMed Web of Science ®Google Scholar
• Bai M, Agnantis NJ, Skyrlas A, et al. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol 2003;16:471–480.
   PubMed Web of Science ®Google Scholar
• Bai M, Skyrlas A, Agnantis NJ, et al. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the pro-apoptotic proteins bax, bak and bid and low expression of the anti-apoptotic protein bcl-xl. Mod Pathol 2004;17:847–856.
   PubMed Web of Science ®Google Scholar
• Bai M, Tsanou E, Skyrlas A, et al. Alterations of the p53, Rb and p27 tumor suppressor pathways in diffuse large B-cell lymphomas. Anticancer Res 2007;27:2345–2352.
   PubMed Web of Science ®Google Scholar
• Campuzano-Zuluaga G, Cioffi-Lavina M, Lossos IS, et al. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. Leuk Lymphoma 2013;54:2405–2411.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013;121:2715–2724.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275–282.
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Goussia A, Voulgaris E, et al. High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype and response to treatment. Leuk Lymphoma 2010;51:1260–1268.
   PubMed Web of Science ®Google Scholar
• Gaudio F, Giordano A, Perrone T, et al. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Acta Haematol 2011;126:44–51.
   PubMed Web of Science ®Google Scholar
• Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010;28:4170–4176.
   PubMedGoogle Scholar
• Sanchez E, Chacon I, Plaza MM, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998;16:1931–1939.
   PubMed Web of Science ®Google Scholar
• Dai B, Zhao XF, Mazan-Mamczarz K, et al. Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma. Nature Com 2011;2:402–407.
   PubMed Web of Science ®Google Scholar
• De J, Brown RE. Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with non-Hodgkin's lymphoma. Int J Clin Exp Med 2010;3:55–68.
   PubMed Web of Science ®Google Scholar
• Gururajan M, Chui R, Karuppannan AK et al. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 2005;106:1382–1391.
   PubMed Web of Science ®Google Scholar